|Security||BIOP / Riot Blockchain, Inc. (767292905)|
|President, CEO, Chairman||O'Rourke John R. III|
|Industry||In Vitro and In Vivo Diagnostic Substances|
|Common Shares Outstanding||13,475,132 shares (as of 2018-03-31)|
RIOT / Riot Blockchain Inc|
Institutional Stock Ownership and Shareholders()
Riot Blockchain, Inc. (NASDAQ:BIOP) has 2 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
Largest shareholders include
Group One Trading, L.p., Group One Trading, L.p., and Simplex Trading, Llc.
Riot Blockchain, Inc. (NASDAQ:BIOP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|GROUP ONE TRADING, L.P.||Call||381,500||2,526|
|Marathon Trading Investment Management LLC||Call||106,100||0||-100.00||3,013||0|
|SNS Financial Group, LLC||Call||108,900||0||-100.00||0||0|
|North Fourth Asset Management, Lp||Put||5,000||0||-100.00||142||0|
|SIMPLEX TRADING, LLC||Call||3,027||725||-76.05||1,031||20||-98.06|
|GROUP ONE TRADING, L.P.||Put||141,100||934|
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Just one day after scaling its 50-day moving average for the first time since May, bitcoin gained early Tuesday as the world’s largest cryptocurrency hopes to extend its recent rally in the face of another potential scandal. (48-0)
CASTLE ROCK, CO / ACCESSWIRE / July 12, 2018 / Riot Blockchain, Inc. (NASDAQ: RIOT) (the "Company") announced that the Company will be participating in Oppenheimer's 21st Annual Technology, Internet & Communications Conference Blockchain Panel in Boston on Tuesday, August 7. (18-0)
CASTLE ROCK, CO / ACCESSWIRE / July 9, 2018 / Riot Blockchain, Inc. (NASDAQ: RIOT) (the "Company") announced its unaudited cryptocurrency mining production yield for the month of June 2018. (18-2)
CASTLE ROCK, CO / ACCESSWIRE / June 27, 2018 / Riot Blockchain, Inc. (NASDAQ: RIOT) (the "Company") announced that it was selected to be added to the Russell Microcap Index effective after the U.S. market opened on June 25, 2018, when the Index reconstituted.
Chicago, IL – June 25, 2018 – Zacks Equity Research highlights HollyFrontier Corporation (HFC - Free Report) as the Bull of the Day, Culp Inc. (CULP - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on CME Group (CME - Free Report) , Riot Blockchain (RIOT - Free Report) and Bitcoin Investment Trust (GBTC - Free Report) . (90-0)
as of ET